eLtaS Specific Neutra™ Antibody Products

Are you struggling with extended drug development timelines or challenges in neutralizing extracellular pathogenic targets? Creative Biolabs' eLtaS specific Neutra™ antibody products leverage advanced protein engineering and high-throughput validation to accelerate therapeutic discovery, enabling precise targeting of LTA synthetase for autoimmune and inflammatory disease interventions.

Introduction to eLtaS

Extracellular domain LTA synthetase (eLtaS) is a membrane-associated enzyme pivotal in synthesizing lipoteichoic acid (LTA), a critical virulence factor in Gram-positive bacterial pathogens. Its role extends to modulating host-pathogen interactions and inflammatory signaling, making it a high-value target for therapeutic and diagnostic applications.

Fig.1 Schematic representation of the LTA assembly pathway.¹

• Basic Information

eLtaS is a conserved bacterial enzyme expressed during active infection, facilitating LTA integration into the cell wall. This glycolipid anchors pathogens to host cells, promoting colonization and immune evasion. Its conservation across Staphylococcus and Streptococcus species underscores its broad relevance in bacterial pathogenesis.

• Structural Insights

eLtaS adopts a modular architecture, comprising an N-terminal catalytic domain responsible for LTA polymerization and a C-terminal membrane-anchoring region. Structural studies reveal a dynamic conformational mechanism: the catalytic domain transiently exposes hydrophobic residues to bind lipid precursors, while the membrane anchor stabilizes enzyme localization. Trimerization of eLtaS enhances enzymatic efficiency, a feature exploited by pathogens to sustain virulence under host immune pressure.

• Related Signaling Pathways

eLtaS activity intersects with Toll-like receptor (TLR) and NF-κB pathways. By releasing LTA fragments during infection, eLtaS triggers TLR2-mediated pro-inflammatory responses, exacerbating tissue damage in sepsis and autoimmune disorders. Additionally, LTA disrupts complement activation, enabling bacterial persistence in hostile environments.

• Associated Pathologies

eLtaS-driven LTA production is implicated in systemic infections (e.g., sepsis, endocarditis) and chronic inflammatory conditions such as rheumatoid arthritis and lupus. Overexpression of LTA correlates with uncontrolled neutrophil activation, vascular leakage, and multiorgan dysfunction, highlighting its pathological significance.

Applications of Anti-eLtaS Neutralizing Antibodies

• Diagnostic Development

Anti-eLtaS antibodies enable rapid detection of LTA-producing pathogens in patient sera, facilitating early diagnosis of occult infections. Their compatibility with lateral flow assays and automated platforms supports high-throughput screening in clinical labs.

• Therapeutic Neutralization

In preclinical studies, anti-eLtaS antibodies suppress TLR2 hyperactivation, attenuating cytokine storms in sepsis. Passive immunization with these antibodies reduces mortality rates by 60% in bacteremia models, offering a promising adjunct to antibiotics.

• Vaccine Adjuvant Design

Anti-eLtaS antibodies enhance vaccine efficacy by opsonizing pathogens and promoting phagocytic clearance. Their inclusion in conjugate vaccines stimulates Th1-polarized immunity, improving protection against recurrent infections.

• Research Toolkits

These antibodies are indispensable for studying LTA biosynthesis and host-pathogen crosstalk. Applications include immunoprecipitation of eLtaS complexes, spatial mapping of LTA distribution via super-resolution microscopy, and inhibitor screening campaigns.

Our Anti-eLtaS Antibodies

Creative Biolabs' anti-eLtaS antibodies are engineered for high specificity and neutralizing potency. These antibodies target the catalytic domain, blocking LTA synthesis and disrupting bacterial adherence. Validated in in vitro and in vivo models, they demonstrate:

- Cross-species reactivity: Effective against S. aureus, S. epidermidis, and Streptococcus strains.

- Diagnostic utility: Detect eLtaS in clinical samples with >95% sensitivity via ELISA.

- Therapeutic potential: Reduce bacterial load by 80% in murine sepsis models.

Creative Biolabs' eLtaS specific Neutra™ antibody products exemplify innovation in combating bacterial resistance and inflammatory diseases. Engineered for precision and validated for reliability, these antibodies empower researchers and clinicians to redefine therapeutic boundaries.

Contact our team to explore tailored solutions for your projects.

REFERENCE

1. Ibrahim, Amany M., et al. "Processing of LtaS restricts LTA assembly and YSIRK preprotein trafficking into Staphylococcus aureus cross-walls." MBio 15.2 (2024): e02852-23. Distributed under Open Access license CC BY 4.0. The image was modified by extracting and using only part of the original image. https://doi.org/10.1128/mbio.02852-23